BeyondSpring highlights confirmatory Phase 3 DUBLIN-4 trial plan for plinabulin in post-ICI NSCLCPUBT·Sep 1 at 11:12 AMBYSI-0.66%
BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approachPUBT·Aug 16 at 01:53 AMBYSI-0.66%
BeyondSpring Q2 FY26 net loss narrows to $1.8 million; cash falls to $6.5 millionPUBT·Aug 14 at 09:15 PMBYSI-0.66%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·Aug 14 at 12:06 PMHCTI-7.79%BYSI-0.66%
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.benzinga_article·Aug 13 at 06:29 PMBYSI-0.66%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Aug 13 at 05:05 PMBYSI-0.66%OMER-0.84%
BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipelinePUBT·Jul 9 at 06:18 PMBYSI-0.66%
BeyondSpring files Form 3 for CFO Na Li showing no beneficial ownershipPUBT·Jul 6 at 05:09 PMBYSI-0.66%
BeyondSpring amends filing to disclose CEO Min Qiu pay package, including USD 100,000 salaryPUBT·Jun 29 at 08:31 PMBYSI-0.66%
BeyondSpring appoints Min Qiu as CEO and Na Li as CFO; Lan Huang to remain as ChairTradingView·Jun 4 at 11:33 AMBYSI-0.66%
